|
 |
|||||||
 |
PRESS RELEASES Biokeys Pharmaceuticals Inc. Consolidates Operations to San Diego SAN DIEGO--Feb. 10, 2003--Biokeys Pharmaceuticals Inc. (OTCBB:BKYS - News) is pleased to announce the addition of Steven Plumb as Chief Financial Officer. Prior to his new position with the Company, he served as a consultant to the Company and was intimately involved in the internal preparation of the Company's financial statements during 2002. Mr. Plumb is President of Steven M. Plumb, P.C., a business consulting firm headquartered in Houston, Texas, that provides accounting and technology services to companies to streamline and manage their accounting operations. He has over 20 years experience in accounting and consulting in a diverse array of industries, including biotechnology, healthcare, and telecommunications. Prior to starting his own firm in 1992, Mr. Plumb served as the Chief Financial Officer of DePelchin Children's Center and as a controller of Memorial City Rehabilitation Hospital, both in Houston, Texas. He is also a former auditor for and consultant with KPMG. Mr. Plumb earned his BBA degree in accounting from the University of Texas in Austin, Texas in 1981. He is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants and a member of the Information Technology section of the American Institute of CPAs. He is also a popular speaker on Accounting Technology. In addition to recent management, board, and capital structure changes, Biokeys Pharmaceuticals, has engaged JH Cohn as auditors of the Company's financial statements. J.H. Cohn is one of the leading independent accounting and consulting firms in the U.S., and one of the largest in the New York/New Jersey metropolitan area. The J.H. Cohn Team consists of more than 65 partners and 400 other professionals and support staff. While many of J.H. Cohn's clients include large, publicly-traded companies, the majority of its practice is devoted to serving mid-size, closely-held proprietorships, partnerships, and corporations that desire a close relationship with their accounting firm. More information about Biokeys Pharmaceuticals can be found on their newly updated website at www.bkys.com. About BKYS Biokeys Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses its energy in cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. The Company's lead compound, CoFactor™, is a chemotherapy biomodulator designed to be used in conjunction with 5-FU, the world's most frequently used cancer drug. CoFactor is being readied to enter Phase II/III human clinical trials in the U.S. and Europe. In the pipeline is BlockAide/CR™, a representative of the new "fourth modality" of HIV therapeutics that works by blocking viral entry and infection of human immune system cells. Also in development is EradicAide™, a cell mediated, antibody-negative therapeutic vaccine for HIV Infection/AIDS. In primate trials, EradicAide has demonstrated the ability to reduce HIV viral loads to undetectable levels, reduce HIV transmissibility and delay progression to AIDS. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contact: Biokeys Pharmaceuticals Inc. Nicholas Virca, President & CEO 858/271-9671 Fax: 858/271-9678 info@bkys.com |
